Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.46 |
| ▸ | RAB9A | P51151 | 10/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.46 |
| ▸ | RELA | Q04206 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | C1R | P00736 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5553573 | 0.77 | RAB9A (0.52) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1946632 | 0.77 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5551673 | 0.77 | NOTUM (0.50) | L3MBTL1MAPK1NOTUMC1RALDH1A1 | |
| SCHEMBL4938081 | 0.77 | EPHX2 (0.36) | NPC1RAB9ASMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL795461 | 0.71 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6451424 | 0.69 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1546047 | 0.68 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2NOTUMKDM4E | |
| SCHEMBL13202083 | 0.67 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL30059833 | 0.67 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3683732 | 0.65 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4101846-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2023-08-02 | — | — | EP | claimed |
| US-7304070-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | claimed |
| US-20050101778-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2005-05-12 | — | — | US | claimed |
| CN-115141120-A | Electrooxidation preparation method of astallurens | 湖南大学 | 2022-10-04 | — | — | CN | disclosed |
| EP-2559689-B1 | Preparation process for crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]benzoic acid | PTC THERAPEUTICS INC (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-2559689-A1 | Preparation process for crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]benzoic acid | PTC Therapeutics, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| CN-102459595-A | Inosine-containing oligonucleotides for the treatment of DMD | PROSENSA TECHNOLOGIES BV | 2012-05-16 | — | — | CN | disclosed |
| EP-2007365-A2 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC Therapeutics, Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007117438-A2 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101778-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | NPC1 2702/4885RAB9A 1704/4885SMN1; SMN2 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.